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Background: Several studies suggest that Vitamin D (Vit-D3) supplementation reduces Chronic Urticaria (CU) symptoms.
Objectives: Evaluation of serum 25-hydroxyvitamin-D (25 (OH)2D) level and assessment of therapeutic effect of VitD3in
CU patients.
Methods: 192 subjects were stratified according to the baseline 25(OH)2D levels and subsequently randomized into
three subgroups to receive Vit-D3 alone (VD) or antihistamine and systemic corticosteroid (H+S) or VitD3 with
antihistamine and systemic corticosteroid (VD+H+S) for 6 weeks between July 2012 to Oct 2014. 130 healthy controls
(HC) were followed without any intervention. The patients were evaluated for reduction in urticarial symptoms using
visual analogue scale (VAS) and 5-D itch score.
Results: Low serum levels of 25 (OH)2D was observed in 91% of CU patients and 64% of the healthy controls (P < 0.0001).
VAS and 5-D Score in subgroups VD, H + S and VD+H+ S decreased significantly from 6 · 7 ± 0 · 043, 6 · 6 ± 0 · 42 and
6 · 68 ± 0 · 40 at baseline to 5 · 2 ± 0 · 70 (P = 0 · 0088), 3 · 3 ± 0 · 50 (P < 0 · 0001) and1 · 86 ± 0 · 39 (P < 0 · 0001) after
treatment and from 14 · 5 ± 0 · 72, 13 · 9 ± 0 · 77 and 13 · 9 ± 0 · 221 to 12 · 06 ± 1 · 10 (P = 0 · 0072), 8 · 1 ± 1 · 13 (P < 0 · 0001)
and 5 · 01 ± 0 · 94 (P < 0 · 0001) respectively.
Conclusions: CU patients have low serum 25(OH)2D levels and Vit-D3 supplementation in combination with
antihistamine and systemic corticosteroid show elevated response in resolving the symptoms of CU. This study
also warrants that each subject with CU should be screened for serum 25 (OH)2D levels before starting a treatment.
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CU is defined as the presence of evanescent wheals which re-
occur for greater than 6 weeks[1]. CU is allergic skin derma-
tosis, and despite extensive evaluation for underlying causes
or triggers, the etiology remains unclear[2]. CU is a common
skin disease that is rarely life threatening, however the high
incidence and prevalence make it a paramount public
health problem, which has protracted course and can
result in significant morbidity[3]. Antihistamines and sys-
temic steroids form the basis of treatment, but response
is often incomplete [4]. Although second–line therapies,* Correspondence: roohi_wani@yahoo.com
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unless otherwise stated.such as cyclosporine[5] and anti IgE therapy (omalizumab)
[6], have been shown to be effective in randomized
controlled trials, there are concerns about costs and
adverse side effects associated with these therapies[7].
There are numerous studies suggesting potential role of
Vit D in improving health outcomes, as far as allergic dis-
orders are concerned. High prevalence of Vit D deficiency
has also been reported in north Indian population[8].
Prevalence of atopic disorders in Vit D deficient patients
when compared withVit D sufficient patients showed an
increased risk of atopic dermatitis among those patients
who were Vit D deficient. However, there was no signifi-
cant difference in the risk of asthma or allergic rhinitis be-
tween Vit D deficient patients and Vit D sufficient
patients[9]. Vit D deficiency has been shown to correlateThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[10]. Conversely, other studies have shown an association
between high Vit D levels and the development of allergic
rhinitis[11].
Although the molecular mechanism underlining the
relation between CU and Vit D is still unknown, Vit D
has been shown to play a considerablerole in the immune
responses generated by antigen-presenting cellsthat has
been recognized with the discovery of Vit D receptors
(VDRs) on these cells[12]. VDRs have been present on a
variety of cells, including keratinocytes and numerous
cells of immune system (e.g. T cells, B cells, neutrophils,
macrophages, and dendritic cells) [13]. The scope of
biological role of the action of Vit D through VDRs
helped clarify the link between Vit D and immune
functions[14]. Also, Vit D affects innate and adaptive
immunity through the stimulation of Toll-like recep-
tors, increasing pro-inflammatory cytokine production,
and possibly enhancing T helper type 2 responses, thereby
defining the possible association of Vit D to allergic
disorders. Many reports suggest a possible influence of
Vit D on prevalence of allergic diseases even though
results are still conflicting [15].
Though there have beenfewer studies that have evalu-
ated the potential link between Vit D and urticaria[16,17],
we sought to determine whether a relationship between
Vit D and CU exists.
Though there have been mixed reviews about the use
of Vit D as treatment in CU,Vit D has been successfully
used as a treatment modality in psoriasis and lupus
vulgaris[18,19]. Skin lesions were resolved when Vit D
insufficiency was treated with oral supplementation of
Vit D[20]. Likewise no cutaneous consequences of low
Vit D are described in Holick’s extensive reviews of the
health implications of Vit D deficiency and inadequacy
[21]. Recently it has been determined that a high dose
(4,000 IU/day) of Vit D3 is more beneficial than a low
dose (600 IU/day) which can be used as an add-on
therapy in CU patients. High dose of Vit D3 can be
considered as safe in patients with CU[22].
In light of several conflicting hypotheses, we con-
ducted a randomized controlled study to investigate
the efficacy and therapeutic benefits of different treat-
ment regimens with and without Vit D3supplementa-
tion inCU patients.Methods
Study population
Patients aged 18 to 60 years with a clinical diagnosis of
moderate-to-severe CSU were evaluated in the present
investigation. The criteria for CSU severity was assessed
according to the classified consensus guidelines from
the European Academy of Allergology and ClinicalImmunology [EAACI] and the World Allergy Organization
[WAO] [23,24].
Evaluation of the CU symptoms
The 5-D itch scale is a multidimensional questionnaire
designed to be useful as an outcome measure in clinical
trials[25]. The five dimensions are;degree, duration,
direction, disability and distribution of pruritus per
24 hours. The scores of each of the five domains are cal-
culated separately and then summed together to obtain a
total 5-D score. 5-D scores can potentially range between 5
(no pruritus) and 25 (most severe pruritus). Randomization
was performed by using a validated system that auto-
mated the random assignment of the treatments to
randomization numbers. The present investigation con-
sisted of a pre-screening visit, a 4 week screening period
and a 6 week treatment period and 4 weeks follow up. At
the prescreening visit, informed consent was obtained,
and patients were assessed for eligibility. VAS was used as
a method of pruritis assessment in CSU patients[26].
Inclusion criteria
The patients with persistent symptoms for more than
6 weeks at screening, body weight between 25 and
100 kg, a total serum IgE level ranging between 30 IU/mL
to700 IU/mL, and a weekly 5-D score of 10 or greater and
visual activity score (VAS) of 5 or greater at the end of
screening were eligible for enrollment in the study. Serum
25 (OH)2D levels <10 ng/ml reflect severe Vit D defi-
ciency, levels between 10–20 ng/ml depicted as deficient,
levels 20–30 ng/ml were described as insufficient and 25
(OH)2D levels of > 30 ng/ml were defined as sufficient
levels [27,28].
Exclusion criteria
Patients having lesions that last more than 24 hours, and
having physical urticaria syndromes were not included
in this study. Patients were excluded if they had received
antihistamines, systemic steroids or immunosuppressive
therapy during the preceding 3 months. Patients that were
having morbidity like diabetes, hypertension, dermatitis
herpetiformis and mastocytoma and any form of kidney
disease were also excluded. Patients having hypercalcemia
or any other calcium disorders were also excluded from
the study. Patients with urticaria caused by infection, food
allergy and drug allergy were also excluded.
Baseline investigations
Baseline investigations in all patients included a routine
laboratory tests like full blood count, erythrocyte sedi-
mentation rate, urine analysis, serum glucose, hepatic
functions and creatinine. Patients were also tested for
hepatic serology, thyroid function test, antinuclear and
anti-thyroid microsomal antibodies. Chest X-ray and
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tients. The patients also underwent the detection for
Helicobacter pylori. Autologous serum skin testing
(ASST), skin prick test (SPT) were also performed on
all patients.
Safety assessment
Safety assessment included the monitoring and recording
the severity of adverse events, along with evaluation of
their duration and relationship to the study. In addition,
routine urine analysis, regular monitoring of hematology
and blood chemistry results and assessment of vital signs
and body weight were performed[24]. Patients were also
monitored for calcium levels at week 2, 4 and 6.
Study design and treatment groups
Measurement properties were analyzed using data from
randomized, parallel- group study of orally administered
Vit D as add-on therapy for the treatment of CSU. 505
patients and 210 normal matched healthy controls were
assessed for eligibility and finallynarrowed down to 192
and 130 respectively from the outpatient department of
Allergy/Immunology ofthe Sher-i-Kashmir Institute ofSub-group: a                        b              
505 Patients Assessed for E
192 Randomized
61 assigned for intervention
59 received Intervention
2 did not receive Intervention
57 assigned for in
55 received Interv
2 did not receive I
11 Lost to Follow-up
• 1 adverse event
• 3 withdrew from study
• 3 Lost to follow-up
• 3 withdrawn by guardian
• 1 migrated
13 Lost to Follow-
• 8 withdrew from
• 3 Lost to follow
• 1 Missed to tak
• 1 moved
48 Completed Study 42 Completed
Figure 1 Enrollment and outcome. 505 patients were enrolled for eligibi
did not fulfill the criteria, 18 patients refused to participate, 8 withdrew bef
abuse were not recruited for the study and 7 did not show up after screen
groups a, b and c. 48 patients in group a, 42 in group b and 57 in group c
events, missed to take the dose, were withdrawn by the guardian or wereMedical Science,Srinagar,in the period between July 2012-
Oct 2014. The study was approved by the ethics commit-
tee of the institutionand was conducted in accordance
with the International Conference on Harmonization
Guidelines for Good Clinical Practice, the ethical prin-
ciples embodied in the Declaration of Helsinki (1989),
and applicable local regulations. Written informed con-
sent was obtained from all patients before their participa-
tion in the study.
Experimental design
Subjects were initially divided into two groups, chronic ur-
ticaria (CU) and Healthy control (HC). 505 patients were
initially screened for the study out of which 63.9% did not
fulfill the eligibility criteria or refused to participate or had
evidence of drug and/or alcohol abuse (Figure 1). Baseline
serum Vit D was evaluated as 25-hydroxyvitamin D
(25(OH)2D) using enzyme immuno assay in all the
subjects. 192 CU patients fulfilling the eligibility cri-
teria,were stratified into 4 Groups. Patients with serum
levels <10 ng/ml reflecting severe vitamin deficiency
were included in group 1. Patients having 10–20 ng/ml
of serum 25 (OH)2 D depicted deficient levels and were                             c
ligibility
276 not meeting inclusion criteria
18 Refused to Participate
8 Withdrew before treatment
4 Had evidence of current  
drug/Alcohol abuse




74 assigned for intervention
73 received Intervention





16 Lost to Follow-up
• 8 withdrew from study
• 3 Lost to follow-up
• 3 Missed  to take a dose
• 1 Withdrew  (unknown cause)
• 1 developed hypercalecemia
 Study 57 Completed Study
lity out of which only 192 fulfilled the eligibility criteria. 276 patients
ore treatment, 4 patients having evidence of current drug/alcohol
ing. 192 patients fulfilling the eligibility criteria were randomized into
completed the study. The rest withdrew from study, had adverse
lost to follow-up.
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of 25 (OH)2 D ranged between 20–30 ng/ml were de-
scribed as insufficient and comprised group 3 and the
patients where 25(OH)2 D levels greater than 30 were
defined as sufficient and comprised group 4. The four
groups were then randomized and treated using three dif-
ferent protocols; a, b and c (Figure 2a).
The four groups were randomized into 3 subgroups a,
b and c. Out of these, 48 in subgroup a, 42 in subgroup
b and 57 in subgroup c completed the study (Figure 2a).
The rest were lost to follow-up, had adverse events, were
withdrawn by guardian, missed a dose or developed hy-
percalcemia (Figure 2b). The experimental design is out-
lined in Figure 2a & b. All subjects satisfying entry
criteria were randomized to receive three different treat-
ment regimens.
In subgroup a (VD), 48patients received oral Vit D3
(cholecalciferol) sachets at a dose of 60,000 IU per week
for 4 weeks.In subgroup b (H + S), 42 patients received,
antihistamine (Hydroxyzine 25 mg) and corticosteroids
(Deflazacort 6 mg)PO daily for 6 weeks. In subgroup c
(VD +H + S), 57 patients received combinatorial therapy
with oral VitD3 sachets at a dose of 60,000 IU per week
for 4 weeks, antihistamine PO, corticosteroids PO daily
for 6 weeks. Healthy control group (n = 130) was followed
as such without any intervention for 6 weeks as described
in protocol d (HC) (Figure 2a). The patients were followed
up to 10 weeks for safety assessment from the start of the
treatment regimen to see if the patients had recurrence of
symptoms or any other off target effects or any adverse
after effects of the treatment.
Monitoring and study end points
Follow up visit was done at two, four and six weeks to
assess the treatment efficacy for CU and any toxic effects
of Vit D. At each visit, any adverse effects of treatment
regimens were recorded. The mean reduction in 5-D
score and VAS after 6 weeks of treatment compared
with the baseline score signifies therapeutic response of
treatment regimens in CU.
Blood was collected at prescreening, at baseline, at
week two, week four and week six after treatment from
each subject of Subgroup a, b, c and d, to evaluate 25
(OH)2VitD levels and to ensure none exceeded moderate
normal values.
Statistical analysis
The sample size was chosen to ensure 85% power for
the primary end point, the mean weekly VAS and 5-D
score, by using a 2-sided 5% significance level to detect a
treatment effect at least as large as its SD (standardized
effect size, >1). Data was expressed as Mean ± standard
error mean (SEM). The difference in the mean values of
Vit D in both the cases and control groups were analyzedby paired t-test to calculate the difference within groups
and Bonferroni independent samples t-test was used to
calculate the level of difference between groups. The pri-
mary end point (VAS and 5D-Score) was evaluated by
using an analysis of covariance model with the factors of
treatment and center and with the baseline score as the
covariate. For the treatment contrast among the three
subgroups a, b and c, a 95% CI and a 2-sided P value
were calculated. Mean score (VAS, 5-D) changes within
subgroup a,b and c were compared, using paired t-test
(keeping normality of the observation into considerations).
Intergroup comparison at different time-points was done
using analysis of variance test (ANOVA). A P < 0 · 05 was
taken to be statistically significant. Statistical analysis
was performed using GraphPad Prism version 6.00 for
Windows (GraphPad Software, San Diego California USA.
Results
Demographics and vitamin D levels
A total of 192CU patients were enrolled in the present
investigation out of which only 147 were considered for
the final evaluation (Figure 2). There was no significant
difference in age of CU Patients (mean years ± SD; 42 ·
83 ± 8 · 52) vs controls (45 · 12 ± 7 · 65)and patients were
predominantly female (67 · 7%). 18 · 9% of patients were
smokers and 25 · 4% of the healthy control had been
smoking over a year. Mean ± SEM Vit D was 17 · 87 ± 1 ·
22 ng/ml for subjects versus 27 · 65 ± 1 · 65 ng/ml for
controls.
Vit D deficiency or insufficiency was seen in 91 · 3% of
the subjects with CU and 63 · 84% of the healthy con-
trols. Vit D levels were significantly lower (P <0 · 0001)
in subjects with CU compared with controls (Figure 3a).
The proportion of all subjects with Vit D deficiencywas
not significantly different between the cases and controls
in men (Figure 3b). However, females with CU had pre-
dominantly lower levels of Vit D (17 · 7 ± 1 · 12 ng/ml)
compared to controls (25 · 44 ± 2 · 24 ng/ml) (**P = 0 ·
0018) (Figure 3b). Also women showed significantly lower
levels of Vit D in comparison to men with CU (P = 0 · 0019)
(Figure 3b) [27,28]. Autologous serum skin test (ASST) re-
sults were positive in 58 · 2%of the patients with CU.
Treatment response
Effect of vitamin D supplementation on serum 25(OH)2D levels
At enrollment, there was no significant difference in
total baseline Vit D levels between subgroups a, b and c
(Figure 3c). After 6 weeks of treatment, subgroup a
undergoing Vit D supplementation alone showed a
3.3 fold increase in serum 25(OH)2D from 16.98 ±
1.43 ng/ml to 56.74 ± 3.76 ng/ml (Mean ± SEM) with
***P < 0 · 0001 (Figure 3c). There was no significant
change in 25(OH)2Dfrom 17.04 ± 1.54 ng/ml to 16.44 ±
1.50 ng/ml in subgroup b (Figure 3c). In subgroup c
Sub-group:  a                             b                                                        c
Group:    1   (n=44)                   2   (n=87)                        3   (n=44)                        4   n=17
CU: Chronic Uriticaria; HC: Heathy Controls; VD: Vitamin D; H+D: Antihistamine + 
Corticosteroids; VD+H+D:  Vitamin D + Antihistamine + Corticosteroids.
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Figure 2 Experimental protocols. a. Vitamin D evaluation and treatment regimen of Chronic Urticaria patients. Patients were stratified
into 4 groups depending upon VitD levels. Group 1, 2, 3 and 4 consisted of patients with serum 25(OH)2D levels <10ng/ml, ≥ 10 ng/
ml to < 20 ng/ml, ≥ 20 to 30 ng/ml and >30ng/ml respectively. All the groups were further randomized into 3 treatment protocol
regimens, a, b and c. 48 Patients in Protocol a received Vitamin D (VD) for 4 weeks, 42 patients in group b received antihistamines and
corticosteroids (H+S) for 6 weeks and 57 patients in group c received a combinatorial therapy of vitamin (4 weeks) + antihistamines+
corticosteroids (VD+H+S) for 6 weeks. 130 healthy controls (HC) in group d were followed as such without any intervention. Patients
were tested for Vit D, VAS and 5D score at the baseline and after 6 weeks of treatment. b. Outline of experiment starting from
recruitment to attaining the end point. Participants were screened for eligibility starting 4 weeks before the start of the experiment
(Screening). The patients that do not fill the eligibility criteria and/or developed secondary disorders during the treatment were
excluded from this study (E₭). Follow up visit for safety assessment was at 2,4,6,8 and 10 weeks after the start of the study (F₴). The
treatment lasted for 6 weeks with follow up and safety assessment for another 4 weeks. The sample size calculations was chosen in a
way that the test for the primary end point, the mean weekly VAS and 5-D score, would have 85% power by using a 2-sided 5%
significance level of the treatment effect (i.e., the difference between the treatment groups) was at least as large as its SD
(standardized effect size, >1).
















































































































Figure 3 Vit D status in CU patients and healthy controls at baseline and after 6 weeks of treatment. a. Quantification of serum 25(OH)2D
levels in CU patients and healthy controls at baseline and after 6 weeks of treatment. Data represents 147 CU patients and 130 healthy controls.
Error bars represent SEM. Paired t-test was used to calculate the difference within groups and Bonferroni independent samples t-test was used to
calculate the level of difference between groups. **P < 0.01and ***P < 0.0001. b. Comparative analysis of baselineVit D levels in male and female
CU patients and healthy controls. Error bars represent SEM. Number of patients in each group is represented in parentheses. **P < 0.01. c. Serum
25(OH)2D levels in CU patients undergoing treatment under three regimens at baseline and after 6 weeks of treatment. Patients were treated
with protocols VD, H + S and VD + H + Sand serum Vit D was measured at baseline and after 6 weeks. Paired t-test was used to calculate the
difference within groups. Error bars represent SEM. **P < 0.01; ***P < 0.0001.
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25(OH)2 D levels from 18.95 ± 1.42 ng/ml to41.73 ±
2.85 ng/ml (***P < 0 · 0001) (Figure 3c).
Subgroup a showed a significant increase in the
serum 25 (OH)2D levels across all the four groups 1–4
(Figure 4a). Group 1,2, 3 and 4 had a baseline 25 (OH)2 D
levels of (Mean ± SEM ng/ml) 4.89 ± 1.2, 14.96 ± 0.57,
23.46 ± 0.93 and 38.95 ± 4.03 which increased to 24.91 ±
0.97 (P < 0.0001), 57.49 ± 3.07 (P < 0.0001), 77.02 ± 9.29
(P = 0.0001) and 71.39 ± 2.44 (P = 0.0006) respectively
(Figure 4a). In subgroup a the patients having critically
low levels of serum 25 (OH)2D before treatment,
showed a 5 fold increase after 6 weeks of treatment.
Group 2 having deficient levels of serum 25 (OH)2D
showed almost 4 fold increase with serum 25 (OH)2D
levels attaining sufficiency. Similarly group 3 having in-
sufficient levels of serum 25 (OH)2D showed 3 fold
increase and attained sufficiency. The patients alreadyhaving sufficient levels of serum 25 (OH)2D also showed
less than 2 fold increase.
There was no significant change in all the four
groups 1–4 in subgroup b (Mean ± SEM ng/ml) 5.642 ±
1.4, 14.69 ± 0.43, 26.54 ± 1.3 and38.21 ± 1.42) when com-
pared to baseline 25(OH)2 D serum levels (5.141 ± 1.23,
14.71 ± 0.55, 24.36 ± 1.00 and 38.58 ± 4.38) respectively
(Figure 4b). In subgroup b the patients did not show
any significant change in any of the 4 groups as
expected.
Subgroup c also showed a significant increase in serum
25(OH)2D levels in group 1, 2 and 3 (Figure 4c). The serum
25(OH)2D levels increased from baseline 4.987 ± 0.97,
14.53 ± 0.59 and 24.28 ± 0.66 to 18.69 ± 2.12 (P < 0.0001),
53.10 ± 4.81 (P < 0.0001) and 41.92 ± 5.06 (P = 0.0043)
respectively. However, group 4 did not show any signifi-
cant increases from baseline 37.22 ± 2.38 to 44.56 ± 2.67 at
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Figure 4 Serum 25(OH)2D levels in CU patients undergoing treatment under three treatment regimens at baseline and after 6 weeks
of treatment. a. Patients were treated with protocols VD and serum Vit D was measured at baseline and after 6 weeks. Paired t-test was used to
calculate the difference within groups. Error bars represent SEM. ****P < 0.0001. b. Patients were treated with protocols H + S and serum Vit D was
measured at baseline and after 6 weeks of treatment. c. Patients were treated with protocols VD + H + S and serum Vit D was measured at baseline
and after 6 weeks of treatment. The arrow depicts the patient that developed hypercalcemia. d. Vit D levels in controls subjects. Paired t-test
was used to calculate the difference within groups. Error bars represent SEM. **P < 0.01; ****P < 0.0001. Vitamin D (VD), Hydroxizine (H) and
Deflazacort (S).
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ment, showed a 3.7 fold increase after 6 weeks of
treatment. Group 2 having deficient levels of serum 25
(OH)2D showed 3.6 fold increase with serum 25 (OH)
2D levels attaining sufficiency. Group 3 having insuffi-
cient levels of serum 25 (OH)2D showed less than 2
fold increase and attained sufficiency. However the
change was not significant when compared to group 3
of subgroup a. One patient in group 3 subgroup c
showed an elevated vitamin D after 4 weeks of treat-
ment with combinatorial therapy. The patient when
evaluated for for basic biochemistry showed an ele-
vated serum calcium levels. After stopping the treat-
ment the patient retained normal calcium levels in lessthan 2 days. In this time the patent was monitored
continuously.
Healthy Control group did not show any significant
change in all the four groups with serum 25(OH)2 D levels
at baseline (7.310 ± 0.52, 15.26 ± 0.47, 23.98 ± 0.46 and
47.78 ± 2.23) to (5.899 ± 0.28, 16.96 ± 1.26, 23.15 ± 0.95
and 49.18 ± 2.97) (Figure 4d). All the groups of control
subgroup d did not show any change in serum 25 (OH)2D
levels as expected.
Moreover, no adverse effects were observed in the
study subjects after two, four and six weeks of treatment
except for one patient that developed hypercalcemia in











































































Figure 5 Effect of Vitamin D supplementation in different
therapy protocols for CU: a. Effect of Vitamin D (VD), antihistamines
(H) and corticosteroids (S) on VAS of CU patients. Patients were treated
with VD alone, H + S and VD + H + S for 6 weeks. VAS was calculated at
the start of the study (baseline) and after 6 weeks of treatment. Values
are presented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***,P < 0.0001.
Number of patients in each group is represented in parentheses.
b. Effect of Vitamin D (VD), antihistamines(H) and corticosteroids (S) on
5-D score of CU patients. Patients were treated with VD alone, H + S
and VD+ H + S for 6 weeks. 5-D score was calculated at the start of the
study (baseline) and after 6 weeks of treatment. Number of patients in
each group is represented in parentheses. Values are presented as
mean ± SEM. *, P < 0.05; **, P < 0.01; ***,P < 0.0001. The primary end
point (VAS and 5D-Score) was evaluated by using an analysis of
covariance model with the factors of treatment and center and
with the baseline score as the covariate. For the treatment contrast
between the three groups a, b and c, a 95% CI and a 2-sided P value
were calculated. Mean score (VAS, 5-D) changes within group VD and
group H + S and group VD+H + S were compared, using paired t-test
(keeping normality of the observation into considerations). Intergroup
comparison at different time-points was done using analysis of variance
test (ANOVA). A P < 0 · 05 was taken to be statistically significant.
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The mean VAS score in subgroupadecreased signifi-
cantly from a baseline score of 6 · 7 ± 0 · 043 to the score
of 5 · 2 ± 0 · 70 with *P = 0 · 0088(Figure 5a). The mean VAS
score of subgroup b was significantly reduced to half from
6 · 6 ± 0 · 42 at baseline to 3 · 3 ± 0 · 50 with ***P < 0 · 0001
(Figure 5a). Similarly the mean VAS score in subgroup
cwas reduced significantly by 3 · 6 fold from baseline
6 · 68 ± 0 · 40 to 1 · 86 ± 0 · 39 with***P < 0 · 0001(Figure 5a).
Comparing inter group VAS score there was a significant
differencein subgroup b compared to subgroup a (*P = 0 ·
0106) at week 6. Subgroup a also showed a significant
difference in VAS when compared to the subgroup c
(***P < 0 · 0001), VAS score in subgroup calso showed
a significant differencein comparison to subgroup b
with *P = 0 · 0203(Figure 5a).
5-D itch score
The mean 5-D itch score in subgroup adecreased signifi-
cantly from a baseline score of 14 · 5 ± 0 · 72 to the score
of 12 · 06 ± 1 · 10 with **P = 0 · 0072(Figure 5b). The mean
5-D score of subgroup b was significantly reduced to
half from 13 · 9 ± 0 · 77 at baseline to 8 · 1 ± 1 · 13with
***P < 0 · 0001 (Figure 5b). Similarly the mean 5-D
score in subgroup c was reduced significantly by 2 · 8
fold from 13 · 9 ± 0 · 68 to 5 · 01 ± 0 · 94 with ***P < 0 ·
0001(Figure 5b).
Comparing inter subgroup 5-D score there was a sig-
nificant difference in subgroup b compared to subgroup
a (*P = 0 · 0116). Subgroup a also showed a significant
difference in 5-D score when compared to the group c
(***P < 0 · 0001). 5-D score in subgroup c also showed a
significant difference in comparison to subgroup b with
*P = 0 · 0382 (Figure 5b).
Discussion
CU encompasses a heterogeneous group of disorders
with diverse underlying etiologies. However, upto 40% of
patients with CU are autoimmune in nature, demon-
strate auto antibodies against either high-affinity IgE re-
ceptors (FcƐRI subunit) or IgE antibody on mast cell
surfaces[3]. Degranulation of mast cells with release of
histamine is central to the pathogenesis of urticaria[29].
H1 antagonists are firmly established as first line therapy
for CU with adjunctive support from medications of
other classes, such as antileukotrienes, immunosuppres-
sive and anti-inflammatory agents (including steroids
and cyclosporine) [30],[31]. Vit D has anti-inflammatory
properties, as observed by the 1, 25 (OH) 2 D mediated
reduction of dendritic cell (DC) maturation [32]. Fur-
thermore, Vit D contributes to the conversion of CD4+
T cells to T regulatory cells, which have been shown to
play a role in the suppression of pro-allergic mecha-
nisms[33].
Rasool et al. World Allergy Organization Journal  (2015) 8:15 Page 9 of 10Vit D deficiency is presently a major health problem in
both adults and children across the globe and highly
prevalent in Indian sub-continent [8,34,35]. The study
population was predominately ethnic, consistent with
the region and had Vit D3 insufficiency or deficiency.
We devised a randomized study to evaluate whether cor-
recting hypovitaminosis D had any therapeutic effective-
ness on CU. Theprimary objective of our study was to
ascertain a potential link between Vit D3 deficiency and
CU and the effect of VitD3 supplementation in repres-
sing the symptoms of CU. A high percent (91.3%) of CU
patients had insufficient or deficient 25 (OH)2D levels
against 63.8% of the healthy control participants, sug-
gesting a possible role of Vit D3deficiency in the patho-
genesis and exacerbation of CU. These findings provide
a detailed investigation of the beneficial effect of Vit D3
supplementation in CU patients. The present investiga-
tion further support and are consistent with the previous
studythat showed CU patients have significantly low
levels of 25 (OH)2D [16] and Vit D3 supplementation de-
creases the CU symptoms and increases the quality of life
of the patients diagnosed with CU [22].
A high dose of Vit D3(60,000 IU/week for4weeks) was
used in the present study because there is high prevalence
of Vit D3 deficiency and/or insufficiency in the Kashmiri
population[8] and beneficial effect of high dose of Vit D3
over low dose in the treatment and recovery of patients
with CU has been reported recently[22]. The notion behind
using Vit D3 instead of Vit D2 in the present investigation
was that Vit D3 is more potent for raising and maintaining
steady-state 25(OH)2D levels than VitD2 [34,36].
CU is intractable skin disease, antihistamines and sys-
temic steroids form the basis of treatment, but response is
often incomplete [4]. An association of pruritus, rash, and
urticaria/ angioedema with low 25(OH)2D <32 ng/mlhas
also been reported,andresolution of symptoms following
Vit D3 replacement was observed in 70% of those patients
with cutaneous symptoms and concurrent Vit D3deficiency
[20], however no detailed extensive study has beenreported
so far on the efficacy of Vit D3 supplementation in resolv-
ing the symptoms of CU. In the present investigation we
observed the patients that receivedVit D3as monotherapy
showed improvement in the CU symptoms. The patients
that received combinatorial therapy showed better im-
provement of symptoms and quality of life than the pa-
tients who received only standard therapeutic regimen [37].
Although the patients receiving Vit D3alone and the pa-
tients receiving standard treatment with Vit D3 supple-
mentation received equal amount of VitD3, there was still
a significant difference in the serum 25 (OH)2D levels be-
tween these twosubgroups, with subgroup a showing sig-
nificantly higher levels of VitD3 then subgroup c. This
difference can be attributed to the effect of systemic corti-
costeroids on the 25 (OH)2D levels [38].Althoughthe course of CU is often quite variable and
protracted;a short follow-up of just 6 week was enough
to show a significant effect on Vit D, VAS and 5-D score.
Furthermore, the patients with CU who exhibit incom-
plete response to drug therapy continue to have symp-
toms, although there might be a reduction in their
symptoms. For this reason, the VAS and 5D-itch score-
sare likely more reliable indicators of treatment response
in short duration studies.
In view of present study, role of Vit D3alone as treat-
ment for CU seems conclusive, although combinatorial
therapy proved more effective form of treatment in pa-
tients with CU. The exact underlying mechanism needs
still to be investigated even though the possible reason
might be adjunctive action from different classes of
drugs in diverse pathogenesis of CU.
Conclusions
Our study showed Vit D3 levels are significantly reduced
in subjects with CU compared with controls. The study
provides a rationale for the selection of Vit D supplemen-
tation as “add-on” therapy for the treatment of CU with
patients showing a greater resolution of CU symptoms.
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